Treatment of ALK Positive Non-small Cell Lung Cancer with Alectinib:
A Case Report and Literature Review / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 673-676, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-922240
ABSTRACT
Lung cancer is a malignant tumor with high incidence rate and mortality rate in China and even the whole world, of which non-small cell lung cancer accounts for about 80%. Anaplastic lymphoma kinase (ALK) gene mutation accounts for about 5%. Alectinib, ALK-tyrosine kinase inhibitor (ALK-TKI), has great performance in clinical. The early detection and treatment of adverse drug reactions can greatly improve clinical benefits. This paper reports a patient of ALK positive non-small cell lung cancer was admited to Baotou Central Hospital in April 2020. The diagnosis and treatment was retrospectively analyzed, and the literature was reviewed.
.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piperidinas
/
Neoplasias Pleurales
/
Carbazoles
/
Tomografía Computarizada por Rayos X
/
Estudios Retrospectivos
/
Carcinoma de Pulmón de Células no Pequeñas
/
Inhibidores de Proteínas Quinasas
/
Quinasa de Linfoma Anaplásico
/
Neoplasias Pulmonares
/
Mutación
Tipo de estudio:
Estudio observacional
/
Estudio de tamizaje
Límite:
Humanos
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS